Masimo (MASI) Scheduled to Post Quarterly Earnings on Tuesday

Masimo (NASDAQ:MASI) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.84 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The business had revenue of $496.30 million during the quarter, compared to analysts’ expectations of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 EPS. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Masimo Trading Up 0.1 %

NASDAQ MASI opened at $144.22 on Monday. The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of 98.11 and a beta of 0.97. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. Masimo has a one year low of $75.36 and a one year high of $153.93. The company’s 50 day moving average price is $129.44 and its 200 day moving average price is $125.14.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Finally, BTIG Research boosted their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Masimo presently has a consensus rating of “Moderate Buy” and an average price target of $145.33.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.